LKFT.US Lakefront Biotherapeutics NV

Healthcare Biotechnology USA Stocks
33.98 USD
Close of Nov 15, 2026
25.68 36.24
Market cap
USD 2.24B
P/E
2.4x
P/B
0.62x
ROE
0.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LKFT.US undervalued?

Graham number

The Graham number of Lakefront Biotherapeutics NV cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lakefront Biotherapeutics NV fundamental analysis

No fundamental analysis for Lakefront Biotherapeutics NV yet.

Lakefront Biotherapeutics NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product ca…

Full company profile